Ownership
Public
Employees
~100
Therapeutic Areas
GastroenterologyPulmonologyImmunologyDermatologyHematologyOncology
Stage
Phase 2
Modalities
Protein therapeuticsProtein therapeutics

Allakos General Information

Lead candidate lirentelimab (AK002) failed Phase 3 trials in eosinophilic gastritis/duodenitis. Company has shifted focus to next-generation Siglec-8 antibody AK006 currently in Phase 2 development.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office

Drug Pipeline

lirentelimab
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Allakos's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Allakos Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Allakos's complete valuation and funding history, request access »